Humanin + MOTS-c + SS-31

This stack is built around what's arguably the cleanest three-axis mechanism story in the peptide longevity space: each component targets a genuinely different aspect of mitochondrial biology, and the three mechanisms don't substantially overlap.

Most peptide stacks rely on the "hit multiple targets, hope for additive effect" argument — defensible at the level of mechanism plausibility, but often pharmacologically thin because the targets share downstream pathways or compete for the same receptors. The mitochondrial triad is different because the three peptides operate on fundamentally separate cellular machinery:

1. Cytoprotection (Humanin). Mitochondrial-derived peptide that binds the FPRL1/WSX-1/gp130 receptor complex on the cell surface and signals through STAT3 to upregulate anti-apoptotic gene expression (Bcl-2 family) and downregulate pro-apoptotic signaling (cytochrome c release, caspase activation). The "prevent mitochondrially-driven cell death" arm. Particularly characterized in neuroprotective contexts (Alzheimer's, Parkinson's, stroke models) and ischemic-injury contexts.
2. Metabolic signaling (MOTS-c). Mitochondrial-encoded peptide that activates AMPK — the cellular energy-sensing kinase that drives metabolic flexibility, fatty acid oxidation, mitochondrial biogenesis, and insulin sensitization. The "tell cells to behave like they're exercising and well-fed" arm. Functions endocrine-style, circulating in blood and signaling whole-body metabolic state across tissues.
3. Structural protection (SS-31 / Elamipretide). Synthetic tetrapeptide that accumulates in the inner mitochondrial membrane and binds cardiolipin — the signature phospholipid of that membrane. By stabilizing cardiolipin under stress conditions, SS-31 preserves cristae architecture and electron transport chain efficiency, reducing reactive oxygen species generation and maintaining ATP production. The "physically keep the mitochondria intact" arm.

The combination logic at the mechanism level: cells under stress (ischemia, aging, metabolic strain) face simultaneous challenges that each mechanism addresses separately. Humanin keeps them from triggering apoptotic programs. MOTS-c keeps the metabolic signaling responsive and adaptive. SS-31 keeps the actual mitochondrial machinery physically functional. None of the three substitutes for the others; each fills a niche that the others don't cover.

This is genuinely different from stacks built around "more is more" reasoning. The triad is built around "different is better" — which is the more pharmacologically defensible argument when combination-specific outcome data is absent.

If you're tracking this against the broader mitochondrial-peptide story, our MOTS-c + SS-31 together or separately article walks through the two-compound decision framework. Adding Humanin extends that framework into a third dimension, with the trade-off that Humanin has the thinnest translational evidence base of the three. For users following NAD+ biology in parallel, our NAD+ precursors guide covers the energy-currency side of mitochondrial function that complements (rather than overlaps with) the three-axis triad.

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

• Does the three-compound combination produce additive or synergistic effects on any measurable endpoint beyond what MOTS-c + SS-31 alone produces?
• Are the subjective effects users attribute to adding Humanin actually distinguishable from MOTS-c + SS-31 plus placebo?
• Does the three-axis approach affect healthspan, lifespan, or biomarkers of aging in any controlled study?
• What are the optimal sequencing and timing patterns — load all three together, or sequence Humanin after MOTS-c + SS-31 stabilization?
• Are there cardiovascular, oncological, or other long-term safety signals from chronic three-compound mitochondrial signaling?
• Will the next decade of clinical trials on individual MDPs (mitochondrial-derived peptides) provide the outcome data the combination rationale needs?
• Does adding NAD+ precursors (NR, NMN, niacin) on top of the triad meaningfully extend benefit, or is it redundant given the substrate vs signaling mechanistic differences?

The Humanin + MOTS-c + SS-31 triad is the cleanest three-axis mitochondrial peptide stack in the current longevity peptide space. The mechanism story is genuinely orthogonal — each compound addresses cellular biology the others don't cover, which is the editorial test that distinguishes mechanistically defensible combinations from redundant or competitive ones. The per-compound evidence is uneven (SS-31 strongest, MOTS-c middle, Humanin thinnest), but each component has reasonable individual research support.

The combination-specific evidence is essentially absent. The stack is being assembled by community users on the basis of mechanism rather than outcome data, which is appropriate to frame honestly: this is an interesting mechanistic bet on the broader mitochondrial-peptide hypothesis, not an evidence-validated clinical intervention. For users committed to the mitochondrial-peptide approach and willing to fund three concurrent compounds, the triad represents the maximum-mechanism-coverage version of the current state of the art. For users wanting the most evidence-based path, the appropriate sequence is SS-31 → MOTS-c → Humanin in order of clinical-evidence credibility, with each addition justified by specific reasons rather than by completeness alone.

If you're evaluating the broader landscape: see our MOTS-c + SS-31 together or separately for the two-compound decision framework, our longevity mitochondrial stack page for the older MOTS-c + Epitalon + SS-31 longevity-triad framing, and our NAD+ precursors guide for the parallel energy-substrate axis that complements rather than overlaps with the three-peptide approach. The triad sits at the cleanest mechanistic intersection of these conversations.

And the underlying point that applies to all aggressive longevity-peptide exploration: the well-supported foundations of healthspan — sleep, exercise, nutrition, cardiovascular and metabolic risk-factor management — produce dramatically larger expected benefits than any peptide stack at any dose. The triad is appropriate as an exploratory layer on top of those foundations, not as substitute for them.